Naoki Tarui

I am the CEO of SEEDSUPPLY INC., a biotech company specializing in drug discovery support through advanced research services. With more than 35 years of experience in pharmaceutical research, I focus on developing innovative approaches to accelerate early-stage drug discovery. At SEEDSUPPLY, we have established the proprietary Binder Selection Technology (BST), an improved Affinity Selection Mass Spectrometry (ASMS) platform that enables direct binding assays with membrane proteins, including challenging targets such as GPCRs, transporters, and ion channels. By integrating our 400,000-compound library with a 17,000-protein panel, we provide unique opportunities to discover novel binders, allosteric modulators, and silent binders that conventional screening methods often miss. My mission is to connect innovative science with therapeutic applications, empowering pharmaceutical and biotech partners worldwide with high-quality screening services and breakthrough insights that open new paths in small-molecule drug discovery.